AHIS, Alliance for Health Implementation Science
TEST BEFORE TREATMENTSponsor the campaign

FAST / Test Before Treatment

TEST BEFORE TREATMENT

A campaign of the FAST Initiative, September 2026 to March 2027

Test before treatment.

Comprehensive genomic testing reads the signature of a patient's cancer and can match them to a targeted therapy, immunotherapy or clinical trial, but only if it's ordered and the results arrive before treatment starts. Test Before Treatment is a clinician-led campaign to make that the standard of care, from September through Biomarker Testing Awareness Month in March.

See the programSponsor the campaign
ShareLinkedInFacebook
When
September 2026 to March 2027
Focus
Comprehensive biomarker testing, from coverage to use
Initiative
FAST
Sponsorship
Open now

Covered isn't the same as tested.

Twenty-five states now require health plans to cover biomarker testing. Coverage opens the door, but it doesn't walk patients through it. The biggest gap in care now sits between coverage and use: tests that aren't ordered, results that arrive after treatment starts, and results that never reach a treatment decision.

Of every 100 patients with advanced non-small cell lung cancer who could benefit from precision medicine, about 36 receive the matched treatment.3 Each step is a handoff, and each handoff can be fixed.

25

states have passed biomarker testing coverage laws.1

39.5%

of patients with advanced lung cancer in community practices were tested for all recommended biomarkers.2

28%

lacked results in time to guide their first treatment.2

We start in Tennessee, where a coverage law takes effect January 1, 2027, and build to Biomarker Testing Awareness Month, nationally, in March.

See the states with coverage laws

1. American Cancer Society Cancer Action Network, updated September 8, 2026; some laws apply to public or private plans only. 2. Thomas CA et al., JCO Oncology Practice, 2026; 306 patients with advanced NSCLC in 30 community practices, 13 recommended biomarkers. 3. Sadik H et al., JCO Precision Oncology, 2022.

Four audiences, one gap.

Closing the gap takes everyone between a covered test and a treatment decision. Each audience has its own plain-language page, materials and messages on the Biomarker Testing Awareness Month site.

Patients & Families

Ask about testing before treatment starts.

Open the Patients and Families page

Oncology Care Teams

Comprehensive testing, ordered every time.

Open the Oncology Care Teams page

Health Systems & Labs

Close the gap from order to result.

Open the Health Systems and Labs page

Payers & Policymakers

For health plans, employers and lawmakers: coverage is the start, not the finish line.

Open the Payers and Policymakers page

September to March.

Six months of field notes, spotlights, webinars and media, each building toward Biomarker Testing Awareness Month.

We'll email you as each chapter is announced. See our Privacy Policy.

  1. SEPT30
    Field Notes

    Field Notes: Employers & Cancer Care

    Tennessee employers are rethinking cancer benefits. Testing belongs in that conversation. From MACC.

    Read the field notesDownload PDF
  2. OCT2026
    Spotlight series

    Monthly spotlights, starting with ESR1 testing

    A short look each month at a part of comprehensive genomic testing, through March.

    Coming soon
  3. NOV19
    Webinar

    From Coverage to Care: A Tennessee Spotlight

    With Gregory Vidal, MD, PhD, of West Cancer Center, and other leaders in cancer care. Thursday, November 19, 1:00 PM CT. Free on Zoom.

    Event detailsRegister on Zoom
  4. WINTER2026
    Report

    January 1 Isn't the Finish Line

    Access and utilization gaps in genomic testing in Tennessee, as biomarker testing coverage takes effect.

    Coming soon
  5. WINTER2027
    Media

    Media push

    Clinician voices, patient perspectives and the data on the gap between covered and tested.

    Coming soon
  6. MAR2027
    Awareness month

    Biomarker Testing Awareness Month

    The national capstone, with its own site: plain-language pages for every audience, materials and a partner wall.

    Visit biomarkertestingawarenessmonth.org

Who's involved.

Clinician-led and locally convened, with sponsors and partners named publicly.

Featured speakers

Gregory Vidal, MD, PhD
Gregory Vidal, MD, PhDWest Cancer Center. Speaking at the November 19 webinar.

Convened by

MACC, Memphis Area Cancer Consortium
MACCMemphis Area Cancer Consortium, an AHIS program. Author of the September Field Notes and supporter of the November 19 webinar.
Sponsors

Sponsors are listed here by level once agreements are signed. Sign by November 5 to be acknowledged at the November 19 webinar.

Become a sponsor

Impact Partners

Advocacy groups, clinics and community organizations are listed here and on the partner wall as they join.

Join free as an Impact Partner

Speakers for each chapter are listed on its event page. AHIS selects all speakers and content, and featured clinicians and speakers disclose relevant relationships.

Choose the role you want to play.

Levels are defined by role, not just amount. Every level is recognition only: no sponsor or partner reviews, approves or shapes campaign content.

Visionary

Leads the campaign.

  • Top placement on the partner wall and this page
  • Named in campaign announcements and the recap
  • Acknowledged at each chapter
  • Seat on the AHIS Sponsor Advisory Council (advisory only)
  • Early access to campaign materials and aggregate results
  • Recap by April 30, 2027, plus a briefing with the AHIS team

Cash sponsorship, with first option to renew

Talk to us about Visionary

Growth

Extends the campaign's reach.

  • Logo in the Growth row of the partner wall and this page
  • Recognition in campaign materials
  • Report on the reach you drove
  • Recap by April 30, 2027

Cash sponsorship, or reach through your patient portals, newsletters or media

Talk to us about Growth

Impact

Delivers the campaign in communities.

  • Logo in the Impact row of the partner wall
  • Partner spotlight post
  • The full campaign toolkit
  • Recap by April 30, 2027

Free, for advocacy groups, clinics, FQHCs, societies and community organizations

Join as an Impact Partner
Sign by November 5

to be acknowledged at the November 19 webinar. Sponsors who join later are recognized from the next chapter on, at the same level and price.

Add a chapter

Visionary and Growth sponsors can fund an added chapter, such as a regional webinar or a translated guide. It becomes part of Test Before Treatment and is credited to all the campaign's sponsors. AHIS selects all speakers and content.

Sponsorship covers the full campaign, from signing through March 31, 2027, with recognition through September 30, 2027. No level carries category or product exclusivity. Pricing and principal terms are in the Sponsor Toolkit.

Built to pass your compliance review.

Test Before Treatment is a disease-awareness campaign. Its value to every sponsor depends on its independence, so independence is built in, not negotiated. How AHIS stays independent

Non-promotional

Campaign content is about biomarker testing: who should ask, when and how to get it. AHIS does not endorse therapies, tests, products or providers.

Guidelines are the source

Recommendations follow current national clinical guidelines and public health sources, with every statistic cited.

AHIS selects all speakers and content

Sponsors do not review, edit or approve patient-facing materials, speakers or agendas. Featured clinicians and speakers disclose relevant relationships.

No exclusivity

Multiple sponsors at every level, including companies whose products or tests compete. No sponsor owns the campaign or the month.

Advisory only

Sponsors may share priorities through the Sponsor Advisory Council, a formal, non-binding channel with published summaries. They never direct content or conclusions.

Named publicly

All sponsors are listed by level. Participation by sponsors, members or partners does not imply AHIS endorsement or preferential treatment.

For your internal routing. This is a disease-awareness sponsorship with recognition benefits, typically funded from patient advocacy, public affairs or disease-awareness budgets. It is not a charitable contribution without benefits, and not an independent medical education grant.

Free to join. A small ask. Real reach.

Advocacy groups, clinics, FQHCs, societies and community organizations carry the message into their communities.

What we ask

  • Share the campaign at least once, ideally in March: a post, a newsletter item or a note to members.
  • Use the campaign mark. The logo pack is ready now; social graphics arrive in February.
  • Optional: tell us about an event or activity, or connect us with a story we could share, with permission.

What you get

  • Your logo on the partner wall at biomarkertestingawarenessmonth.org, linked to your site.
  • A partner spotlight on campaign channels.
  • The full campaign toolkit: messages, graphics and plain-language pages for every audience.
  • The campaign recap in April, to show your members and funders.
Join the partner wallImpact Partner Toolkit (PDF)Logo pack (ZIP)

Follow the campaign.

Use both hashtags and link back to the campaign so people get current information.

Campaign home

This page: every chapter, speakers and registration.

March site

biomarkertestingawarenessmonth.org, with pages for each audience, materials and the partner wall.

Hashtags

#TestBeforeTreatment through the campaign, and #BiomarkerTestingAwarenessMonth in March.